Upadacitinib improves CD, UC in patients with prior tofacitinib failure
Treatment with upadacitinib induces clinical remission and endoscopic improvement in most patients with severe, refractory Crohn’s disease (CD) or ulcerative colitis (UC) with prior tofacitinib failure, regardless of previous response to tofacitinib, a study has shown.
